Cell easy
Cell easy
  • CDMO Services
    • Tissue & Cell Sourcing
    • Process and Analytical Development
    • Manufacturing
    • Analytics testing
    • Regulatory Support
  • Accelerator Platforms
    • CellAnalytics Platform
    • CellProcess Platform
    • MSC4All Platforms
  • About Us
  • Careers
  • News
Cell easy
  • CDMO Services
    • Tissue & Cell Sourcing
    • Process and Analytical Development
    • Manufacturing
    • Analytics testing
    • Regulatory Support
  • Accelerator Platforms
    • CellAnalytics Platform
    • CellProcess Platform
    • MSC4All Platforms
  • About Us
  • Careers
  • News

Manufacturing

HomeBlog GridManufacturing
By Alexis DelbaereJune 22, 2023

IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy

TOULOUSE, FRANCE, June 22, 2023  IUCT-Oncopole and Cell-Easy SAS (Cell-Easy) announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies. This partnership aims to drive innovation in public health and improve access to promising new cancer therapies for patients.   By

+ Read More
By Alexis DelbaereMay 15, 2023

Cell Easy appoints CDMO expert Dr. Sebastien Ribault as Independent Board Director, to accelerate its rapid growth.

TOULOUSE, France _ April 10, 2023 Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells such

+ Read More
By Guillaume LaySeptember 28, 2022

EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

TOULOUSE, France & MONTPELLIER, France _ September 22, 2022 Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the

+ Read More

Brochure

  • Brochure.doc80kb
  • Brochure.pdf80kb

Gallery

Social icon

Let’s Work Together!

+Contact Us
  • Tel : +33 534 276 550
  • Adresse : Cell-Easy SAS, 4 bis avenue Hubert Curien, 31100 Toulouse, France

  • Legal Notice
  • Privacy Policy
  • LinkedIn